Chao Gu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chao Gu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Mei Wang
Department of Pharmacy, Children's Hospital of Soochow University, China
4 shared publications Yajing Chen
Department of Pharmacy Children's Hospital of Soochow University Suzhou China
4 shared publicationsFang Li
Department of Pharmacy Children's Hospital of Soochow University Suzhou China
3 shared publicationsShuwei Yuan
Department of Pharmacy Children's Hospital of Soochow University Suzhou China
3 shared publicationsWenjing Wang
Department of Pharmacy Children's Hospital of Soochow University Suzhou China
3 shared publicationsXiaohuan Du
Department of Pharmacy Children's Hospital of Soochow University Suzhou China
3 shared publications
Latest Publications
- Open Access
- 5 September 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (9) , e71139
P7C3 Compounds as Targeted Mitochondrial Therapeutics for Brain Disorders
Background: P7C3 compounds are aminopropyl carbazole derivatives identified through phenotypic screening for proneurogenic activity. They directly activate nicotinamide phosphoribosyltransferase (NAMPT), the rate‐limiting enzyme in the NAD + salvage pathway. However, a comprehensive synthesis of their mechanisms and therapeutic potential across neurological disorders is currently lacking. Methods: A systematic literature review was conducted in PubMed, Web of Science, and Scopus to synthesize the discovery trajectory, structure–activity relationships, molecular mechanisms, and preclinical efficacy of P7C3 compounds. The following keyword combinations were used: (“P7C3” OR “P7C3 compound”) AND (“NAMPT” OR “NAD+” OR “sirtuin” OR “mitochondria”) AND (“neuroprotection” OR “neurodegenerative”). Results: P7C3 elevates intracellular NAD + levels, engages SIRT1 and SIRT3 deacetylase cascades, enhances mitochondrial quality control and attenuates oxidative stress. This review discusses the discovery, structure–activity relationships, and molecular mechanisms of P7C3, with a particular emphasis on mitochondrial dynamics and redox homeostasis. The efficacy of P7C3 in preclinical studies was evaluated across Alzheimer's disease (AD), Parkinson's disease (PD), traumatic brain injury (TBI), ischemic stroke, depression, and chemotherapy‐induced neuropathy. These neuroprotective effects occur independently of disease‐specific aggregates. Challenges hindering clinical application include the on‐target safety of NAMPT activation given the concurrent development of NAMPT inhibitors for tumorigenesis, the absence of validated predictive biomarkers, and the failure of prior NAMPT‐targeting trials. Conclusions: P7C3 illustrates how phenotypic screening coupled with target deconvolution can yield therapeutic candidates with potential applications across a broad spectrum of neurological disorders.
- 5 September 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (9) , e71139
Open AccessP7C3 Compounds as Targeted Mitochondrial Therapeutics for Brain Disorders
Background: P7C3 compounds are aminopropyl carbazole derivatives identified through phenotypic screening for proneurogenic activity. They directly activate nicotinamide phosphoribosyltransferase (NAMPT), the rate‐limiting enzyme in the NAD + salvage pathway. However, a comprehensive synthesis of their mechanisms and therapeutic potential across neurological disorders is currently lacking. Methods: A systematic literature review was conducted in PubMed, Web of Science, and Scopus to synthesize the discovery trajectory, structure–activity relationships, molecular mechanisms, and preclinical efficacy of P7C3 compounds. The following keyword combinations were used: (“P7C3” OR “P7C3 compound”) AND (“NAMPT” OR “NAD+” OR “sirtuin” OR “mitochondria”) AND (“neuroprotection” OR “neurodegenerative”). Results: P7C3 elevates intracellular NAD + levels, engages SIRT1 and SIRT3 deacetylase cascades, enhances mitochondrial quality control and attenuates oxidative stress. This review discusses the discovery, structure–activity relationships, and molecular mechanisms of P7C3, with a particular emphasis on mitochondrial dynamics and redox homeostasis. The efficacy of P7C3 in preclinical studies was evaluated across Alzheimer's disease (AD), Parkinson's disease (PD), traumatic brain injury (TBI), ischemic stroke, depression, and chemotherapy‐induced neuropathy. These neuroprotective effects occur independently of disease‐specific aggregates. Challenges hindering clinical application include the on‐target safety of NAMPT activation given the concurrent development of NAMPT inhibitors for tumorigenesis, the absence of validated predictive biomarkers, and the failure of prior NAMPT‐targeting trials. Conclusions: P7C3 illustrates how phenotypic screening coupled with target deconvolution can yield therapeutic candidates with potential applications across a broad spectrum of neurological disorders.
- Open Access
- 14 February 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1534660
Research trends of inflammation in autism spectrum disorders: a bibliometric analysis
Background: Inflammation has been recognized as a significant factor in the pathophysiology of autism spectrum disorders (ASD), which have garnered increasing scholarly attention over the past few decades. This study aims to explore research trends related to inflammation and ASD through bibliometric analysis.Method: A comprehensive literature search was conducted in the Web of Science Core Collection (WoSCC) on August 28, 2024. This study was restricted to literature published in English. The bibliometric analysis utilized VOSviewer, CiteSpace, and the R package “bibliometrix” to visualize collaborations, keyword co-occurrences, and emerging research trends.Results: A total of 1,752 articles addressing inflammation and ASD were published, demonstrating a consistent upward trend in research output. The United States emerged as the country with the highest volume of publications. Saleh A. Bakheet was identified as the most prolific authors, significantly contributing to the literature with 54 publications. The University of California System was recognized as the most productive institution in this area of study. The journal of Brain Behavior and Immunity was noted as a prominent venue for publication in this field, exhibiting high citation metrics that reflect its considerable influence. The keyword “children” was the most frequently occurring term, with other significant terms including “oxidative stress” and “brain.” The keyword burst analysis revealed notable periods of increased research focus on topics such as “inflammatory bowel disease,” “cytokine production,” “neurodevelopmental disorders,” and “microbiota.”Conclusion: This bibliometric analysis highlights the growing scholarly attention devoted to the relationship between inflammation and ASD. Significant contributions and emerging trends emphasize the pivotal role of neuroinflammation in ASD, indicating a necessity for further exploration in this domain.
- 14 February 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1534660
Open AccessResearch trends of inflammation in autism spectrum disorders: a bibliometric analysis
Background: Inflammation has been recognized as a significant factor in the pathophysiology of autism spectrum disorders (ASD), which have garnered increasing scholarly attention over the past few decades. This study aims to explore research trends related to inflammation and ASD through bibliometric analysis.Method: A comprehensive literature search was conducted in the Web of Science Core Collection (WoSCC) on August 28, 2024. This study was restricted to literature published in English. The bibliometric analysis utilized VOSviewer, CiteSpace, and the R package “bibliometrix” to visualize collaborations, keyword co-occurrences, and emerging research trends.Results: A total of 1,752 articles addressing inflammation and ASD were published, demonstrating a consistent upward trend in research output. The United States emerged as the country with the highest volume of publications. Saleh A. Bakheet was identified as the most prolific authors, significantly contributing to the literature with 54 publications. The University of California System was recognized as the most productive institution in this area of study. The journal of Brain Behavior and Immunity was noted as a prominent venue for publication in this field, exhibiting high citation metrics that reflect its considerable influence. The keyword “children” was the most frequently occurring term, with other significant terms including “oxidative stress” and “brain.” The keyword burst analysis revealed notable periods of increased research focus on topics such as “inflammatory bowel disease,” “cytokine production,” “neurodevelopmental disorders,” and “microbiota.”Conclusion: This bibliometric analysis highlights the growing scholarly attention devoted to the relationship between inflammation and ASD. Significant contributions and emerging trends emphasize the pivotal role of neuroinflammation in ASD, indicating a necessity for further exploration in this domain.
- Open Access
- 26 July 2024
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (7) , e14819
P7C3 suppresses astrocytic senescence to protect dopaminergic neurons: Implication in the mouse model of Parkinson’s disease
Aims: Astrocytic senescence is inextricably linked to aging and neurodegenerative disorders, including Parkinson's disease (PD). P7C3 is a small, neuroprotective aminopropyl carbazole compound that exhibits anti‐inflammatory properties. However, the effects of P7C3 on astrocytic senescence in PD remain to be elucidated.Methods: An in vitro, long culture‐induced, replicative senescence cell model and a 1‐methyl‐4‐phenylpyridinium (MPP+)/rotenone‐induced premature senescence cell model were used to investigate the effects of P7C3 on astrocytic senescence. An in vivo, 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced mouse PD model was used to study the role of P7C3 in astrocytic senescence. Immunoblotting, real‐time quantitative RT‐PCR (qPCR), immunofluorescence, subcellular fractionation assays, and immunohistochemistry were utilized to confirm the effects of P7C3 on astrocytic senescence and elucidate its underlying mechanisms.Results: This study determined that P7C3 suppressed the senescence‐associated secretory phenotype (SASP) in both cell models, as demonstrated by the reduction in the critical senescence marker p16 and proinflammatory factors (IL‐6, IL‐1β, CXCL10, and MMP9) and increased laminB1 levels, implying that P7C3 inhibited replicative astrocytic senescence and MPP+/rotenone‐induced premature astrocytic senescence, Most importantly, we demonstrated that P7C3 prevented the death of dopamine (DA) neurons and reduced the behavioral deficits in the MPTP‐induced mouse model of PD, which is accompanied by a decrease in senescent astrocytes in the substantia nigra compacta (SNc). Mechanistically, P7C3 promoted Nrf2/Sirt3‐mediated mitophagy and reduced mitochondrial reactive oxygen species (mitoROS) generation, which contributed to the suppression of astrocytic senescence. Furthermore, Sirt3 deficiency obviously abolished the inhibitory effects of P7C3 on astrocytic senescence.Conclusion: This study revealed that P7C3 inhibited astrocytic senescence via increased Nrf2/Sirt3‐mediated mitophagy and suppression of mitoROS, which further protected against DA neuronal loss. These observations provide a prospective theoretical basis for P7C3 in the treatment of age‐associated neurodegenerative diseases, such as PD.
- 26 July 2024
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (7) , e14819
Open AccessP7C3 suppresses astrocytic senescence to protect dopaminergic neurons: Implication in the mouse model of Parkinson’s disease
Aims: Astrocytic senescence is inextricably linked to aging and neurodegenerative disorders, including Parkinson's disease (PD). P7C3 is a small, neuroprotective aminopropyl carbazole compound that exhibits anti‐inflammatory properties. However, the effects of P7C3 on astrocytic senescence in PD remain to be elucidated.Methods: An in vitro, long culture‐induced, replicative senescence cell model and a 1‐methyl‐4‐phenylpyridinium (MPP+)/rotenone‐induced premature senescence cell model were used to investigate the effects of P7C3 on astrocytic senescence. An in vivo, 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced mouse PD model was used to study the role of P7C3 in astrocytic senescence. Immunoblotting, real‐time quantitative RT‐PCR (qPCR), immunofluorescence, subcellular fractionation assays, and immunohistochemistry were utilized to confirm the effects of P7C3 on astrocytic senescence and elucidate its underlying mechanisms.Results: This study determined that P7C3 suppressed the senescence‐associated secretory phenotype (SASP) in both cell models, as demonstrated by the reduction in the critical senescence marker p16 and proinflammatory factors (IL‐6, IL‐1β, CXCL10, and MMP9) and increased laminB1 levels, implying that P7C3 inhibited replicative astrocytic senescence and MPP+/rotenone‐induced premature astrocytic senescence, Most importantly, we demonstrated that P7C3 prevented the death of dopamine (DA) neurons and reduced the behavioral deficits in the MPTP‐induced mouse model of PD, which is accompanied by a decrease in senescent astrocytes in the substantia nigra compacta (SNc). Mechanistically, P7C3 promoted Nrf2/Sirt3‐mediated mitophagy and reduced mitochondrial reactive oxygen species (mitoROS) generation, which contributed to the suppression of astrocytic senescence. Furthermore, Sirt3 deficiency obviously abolished the inhibitory effects of P7C3 on astrocytic senescence.Conclusion: This study revealed that P7C3 inhibited astrocytic senescence via increased Nrf2/Sirt3‐mediated mitophagy and suppression of mitoROS, which further protected against DA neuronal loss. These observations provide a prospective theoretical basis for P7C3 in the treatment of age‐associated neurodegenerative diseases, such as PD.
- 23 December 2022
- Published by Springer Nature in Psychopharmacology
- Vol. 240 (1) , 239-248
The M1 muscarinic acetylcholine receptor regulates the surface expression of the AMPA receptor subunit GluA2 via PICK1
Muscarinic acetylcholine receptors (mAChRs) have been shown to play significant roles in the regulation of normal cognitive processes in the hippocampus, and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) are also involved in these processes. This study aims to explore the mAChR-mediated regulation of AMPARs GluA2 trafficking and to reveal the key proteins and the signaling cascade involved in this process. Primary hippocampal neurons, as cell models, were treated with agonist 77-LH-28-1 and antagonist VU0255035, Fsc231, and APV. C57BL/6J male mice were stereotactically injected with 77-LH-28-1 and Fsc231 to obtain hippocampal slices. The trafficking of GluA2 was detected by surface biotinylation and immunostaining. Activation of M1 mAChRs promoted endocytosis and decreased the postsynaptic localization of the AMPA receptor subunit GluA2 and that phosphorylation of GluA2 at Ser880 was increased by M1 mAChR activity. Fsc231 blocked the endocytosis and postsynaptic localization of GluA2 induced by 77-LH-28-1 without affecting the phosphorylation of Ser880. PICK1 was required for M1 mAChR-mediated GluA2 endocytosis and downstream of phosphorylation of GluA2-Ser880, and the PICK1-GluA2 interaction was essential for M1 mAChR-mediated postsynaptic expression of GluA2. Taken together, our results show a functional correlation of M1 mAChRs with GluA2 and the role of PICK1 in their interplay. Graphical abstract The schematic diagram for the modulation of GluA2 trafficking by M1 mAChRs. Activation of M1 mAChRs induces PKC activation, and the interaction of PICK1-GluA2 determines the endocytosis and postsynaptic localization of GluA2
- 23 December 2022
- Published by Springer Nature in Psychopharmacology
- Vol. 240 (1) , 239-248
The M1 muscarinic acetylcholine receptor regulates the surface expression of the AMPA receptor subunit GluA2 via PICK1
Muscarinic acetylcholine receptors (mAChRs) have been shown to play significant roles in the regulation of normal cognitive processes in the hippocampus, and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) are also involved in these processes. This study aims to explore the mAChR-mediated regulation of AMPARs GluA2 trafficking and to reveal the key proteins and the signaling cascade involved in this process. Primary hippocampal neurons, as cell models, were treated with agonist 77-LH-28-1 and antagonist VU0255035, Fsc231, and APV. C57BL/6J male mice were stereotactically injected with 77-LH-28-1 and Fsc231 to obtain hippocampal slices. The trafficking of GluA2 was detected by surface biotinylation and immunostaining. Activation of M1 mAChRs promoted endocytosis and decreased the postsynaptic localization of the AMPA receptor subunit GluA2 and that phosphorylation of GluA2 at Ser880 was increased by M1 mAChR activity. Fsc231 blocked the endocytosis and postsynaptic localization of GluA2 induced by 77-LH-28-1 without affecting the phosphorylation of Ser880. PICK1 was required for M1 mAChR-mediated GluA2 endocytosis and downstream of phosphorylation of GluA2-Ser880, and the PICK1-GluA2 interaction was essential for M1 mAChR-mediated postsynaptic expression of GluA2. Taken together, our results show a functional correlation of M1 mAChRs with GluA2 and the role of PICK1 in their interplay. Graphical abstract The schematic diagram for the modulation of GluA2 trafficking by M1 mAChRs. Activation of M1 mAChRs induces PKC activation, and the interaction of PICK1-GluA2 determines the endocytosis and postsynaptic localization of GluA2
- Open Access
- 16 November 2021
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 13
Role of G Protein-Coupled Receptors in Microglial Activation: Implication in Parkinson’s Disease
Parkinson’s disease (PD) is one of the prevalent neurodegenerative diseases associated with preferential loss of dopaminergic (DA) neurons in the substantia nigra compacta (SNc) and accumulation of α-synuclein in DA neurons. Even though the precise pathogenesis of PD is not clear, a large number of studies have shown that microglia-mediated neuroinflammation plays a vital role in the process of PD development. G protein-coupled receptors (GPCRs) are widely expressed in microglia and several of them act as regulators of microglial activation upon corresponding ligands stimulations. Upon α-synuclein insults, microglia would become excessively activated through some innate immune receptors. Presently, as lack of ideal drugs for treating PD, certain GPCR which is highly expressed in microglia of PD brain and mediates neuroinflammation effectively could be a prospective source for PD therapeutic intervention. Here, six kinds of GPCRs and two types of innate immune receptors were introduced, containing adenosine receptors, purinergic receptors, metabotropic glutamate receptors, adrenergic receptors, cannabinoid receptors, and melatonin receptors and their roles in neuroinflammation; we highlighted the relationship between these six GPCRs and microglial activation in PD. Based on the existing findings, we tried to expound the implication of microglial GPCRs-regulated neuroinflammation to the pathophysiology of PD and their potential to become a new expectation for clinical therapeutics.
- 16 November 2021
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 13
Open AccessRole of G Protein-Coupled Receptors in Microglial Activation: Implication in Parkinson’s Disease
Parkinson’s disease (PD) is one of the prevalent neurodegenerative diseases associated with preferential loss of dopaminergic (DA) neurons in the substantia nigra compacta (SNc) and accumulation of α-synuclein in DA neurons. Even though the precise pathogenesis of PD is not clear, a large number of studies have shown that microglia-mediated neuroinflammation plays a vital role in the process of PD development. G protein-coupled receptors (GPCRs) are widely expressed in microglia and several of them act as regulators of microglial activation upon corresponding ligands stimulations. Upon α-synuclein insults, microglia would become excessively activated through some innate immune receptors. Presently, as lack of ideal drugs for treating PD, certain GPCR which is highly expressed in microglia of PD brain and mediates neuroinflammation effectively could be a prospective source for PD therapeutic intervention. Here, six kinds of GPCRs and two types of innate immune receptors were introduced, containing adenosine receptors, purinergic receptors, metabotropic glutamate receptors, adrenergic receptors, cannabinoid receptors, and melatonin receptors and their roles in neuroinflammation; we highlighted the relationship between these six GPCRs and microglial activation in PD. Based on the existing findings, we tried to expound the implication of microglial GPCRs-regulated neuroinflammation to the pathophysiology of PD and their potential to become a new expectation for clinical therapeutics.